Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 43,631 shares at $56.95 ($2.5M) on 2021-03-03, disclosed to the SEC on 2021-03-05.
Open-market sale of $2.5M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.91 | 793 | $44K | 1.8% |
| 2 | $55.91 | 518 | $29K | 1.2% |
| 3 | $56.95 | 3,004 | $171K | 7.0% |
| 4 | $56.95 | 1,958 | $112K | 4.5% |
| 5 | $56.95 | 1,958 | $112K | 4.5% |
| 6 | $56.95 | 3,004 |
| $171K |
| 7.0% |
| 7 | $57.79 | 2,903 | $168K | 6.8% |
| 8 | $57.79 | 2,903 | $168K | 6.8% |
| 9 | $57.79 | 1,894 | $109K | 4.5% |
| 10 | $57.79 | 1,894 | $109K | 4.5% |
| 11 | $58.88 | 496 | $29K | 1.2% |
| 12 | $58.88 | 761 | $45K | 1.8% |
| 13 | $54.22 | 1,086 | $59K | 2.4% |
| 14 | $54.22 | 1,662 | $90K | 3.7% |
| 15 | $54.22 | 1,662 | $90K | 3.7% |
| 16 | $54.22 | 1,086 | $59K | 2.4% |
| 17 | $55.21 | 2,962 | $164K | 6.7% |
| 18 | $55.21 | 1,932 | $107K | 4.3% |
| 19 | $55.21 | 1,932 | $107K | 4.3% |
| 20 | $55.21 | 2,962 | $164K | 6.7% |
| 21 | $56.18 | 895 | $50K | 2.0% |
| 22 | $56.18 | 895 | $50K | 2.0% |
| 23 | $56.18 | 1,376 | $77K | 3.1% |
| 24 | $56.18 | 1,376 | $77K | 3.1% |
| 25 | $57.21 | 847 | $48K | 2.0% |
| 26 | $57.21 | 553 | $32K | 1.3% |
| 27 | $58.03 | 126 | $7K | 0.3% |
| 28 | $58.03 | 193 | $11K | 0.5% |
| Total | $56.36 avg | 43,631 | $2.5M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |